Amgen (AMGN)
(Delayed Data from NSDQ)
$337.38 USD
+1.43 (0.43%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $337.36 -0.02 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Company Summary
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology and neuroscience markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining ...
Company Summary
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology and neuroscience markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its blockbuster growth drugs like Prolia and Xgeva. Other products are Repatha, Blincyto, Vectibix, Nplate, Kyprolis, Evenity, Otezla, Aimovig, Lumakras/Lumykras, Tezspire, Tavneos and Kanjinti, Mvasi and Amgevita biosimilars.
In October 2023, Amgen acquired Horizon Therapeutics for $27.8 billion. The acquisition added some rare disease drugs like Tepezza, Krystexxa and Uplizna to its product portfolio.
Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. Biosimilar drugs are also a key part of Amgen’s growth strategy.
Enbrel accounted for 14% of Amgen’s total product sales in 2023. Prolia accounted for 15% of product sales. While Xgeva accounted for 7.8% of sales, Otezla accounted for 8% of Amgen’s product sales in 2023. Repatha accounted for 6% of product sales in 2023.
Amgen derives the bulk of its revenues from the domestic market (71.6% of total product sales in 2023). The company posted global sales of $28.19 billion in 2023, up 7.1% year over year.
General Information
Amgen Inc
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320
Phone: 805-447-1000
Fax: 805-447-1010
Web: http://www.amgen.com
Email: investor.relations@amgen.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/29/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 5.13 |
Current Year EPS Consensus Estimate | 19.49 |
Estimated Long-Term EPS Growth Rate | 5.80 |
Exp Earnings Date | 10/29/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 335.95 |
52 Week High | 346.85 |
52 Week Low | 249.70 |
Beta | 0.61 |
20 Day Moving Average | 1,766,991.62 |
Target Price Consensus | 324.38 |
4 Week | 2.61 |
12 Week | 7.98 |
YTD | 17.14 |
4 Week | 1.39 |
12 Week | 3.40 |
YTD | -2.02 |
Shares Outstanding (millions) | 537.33 |
Market Capitalization (millions) | 181,284.14 |
Short Ratio | NA |
Last Split Date | 11/22/1999 |
Dividend Yield | 2.67% |
Annual Dividend | $9.00 |
Payout Ratio | 0.48 |
Change in Payout Ratio | 0.05 |
Last Dividend Payout / Amount | 8/16/2024 / $2.25 |
Fundamental Ratios
P/E (F1) | 17.31 |
Trailing 12 Months | 18.14 |
PEG Ratio | 3.00 |
vs. Previous Year | -0.60% |
vs. Previous Quarter | 25.51% |
vs. Previous Year | 20.07% |
vs. Previous Quarter | 12.64% |
Price/Book | 30.55 |
Price/Cash Flow | 12.80 |
Price / Sales | 5.86 |
6/30/24 | 161.72 |
3/31/24 | 156.21 |
12/31/23 | 154.27 |
6/30/24 | 10.81 |
3/31/24 | 10.82 |
12/31/23 | 10.95 |
6/30/24 | 1.26 |
3/31/24 | 1.42 |
12/31/23 | 1.65 |
6/30/24 | 0.89 |
3/31/24 | 0.98 |
12/31/23 | 1.13 |
6/30/24 | 32.46 |
3/31/24 | 33.97 |
12/31/23 | 35.59 |
6/30/24 | 10.12 |
3/31/24 | 12.74 |
12/31/23 | 23.83 |
6/30/24 | 11.40 |
3/31/24 | 14.71 |
12/31/23 | 27.86 |
6/30/24 | 11.05 |
3/31/24 | 9.36 |
12/31/23 | 11.65 |
6/30/24 | 1.45 |
3/31/24 | 1.41 |
12/31/23 | 1.38 |
6/30/24 | 9.64 |
3/31/24 | 11.96 |
12/31/23 | 10.14 |
6/30/24 | 90.60 |
3/31/24 | 92.28 |
12/31/23 | 91.02 |